Valuation: COMPASS Pathways plc

Market Cap 1.67B 1.46B 1.34B 1.24B 2.33B 160B 2.39B 16.06B 6.32B 78.61B 6.26B 6.12B 271B P/E 2026 *
-13x
P/E 2027 * -8.7x
Enterprise Value 1.24B 1.09B 1B 924M 1.74B 120B 1.78B 11.98B 4.71B 58.6B 4.67B 4.56B 202B EV / Sales 2026 *
-
EV / Sales 2027 * 19x
Free-Float
25.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: COMPASS Pathways plc

1 day-0.64%
1 week-9.46%
Current month-12.72%
1 month-1.44%
3 months+85.44%
6 months+68.03%
Current year+78.99%
1 week 12.02
Extreme 12.02
14.6
1 month 11.56
Extreme 11.56
15.4
Current year 4.88
Extreme 4.88
15.4
1 year 3.92
Extreme 3.92
15.4
3 years 2.25
Extreme 2.25
15.4
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 31/07/2022
Director of Finance/CFO 54 29/02/2024
Chief Tech/Sci/R&D Officer 66 30/04/2024
Director TitleAgeSince
Chairman 74 28/03/2024
Director/Board Member 69 31/03/2020
Director/Board Member 67 28/02/2021
Date Insider Type Main position Quantity % Market Cap.
27/05/26 Free

Director

21,110 0.0220%
27/05/26 Free

Director

21,110 0.0220%
27/05/26 Free

Director

41,119 0.0429%
Change 5-day change 1-year change 3-year change Capi.($)
-0.64%-9.46%+187.21%+27.06% 1.67B
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average -0.01%-0.92%+79.45%+90.50% 24.53B
Weighted average by Cap. -0.06%-0.24%+80.23%+122.61%

Financials

2026 *2027 *
Net sales - 61.21M 53.49M 49.36M 45.5M 85.75M 5.89B 87.65M 590M 232M 2.89B 230M 225M 9.94B
Net income -100M -87.68M -80.91M -74.58M -141M -9.66B -144M -967M -380M -4.73B -377M -369M -16.29B -197M -172M -159M -146M -276M -18.96B -282M -1.9B -747M -9.29B -740M -723M -31.97B
Net Debt -424M -371M -342M -315M -594M -40.84B -607M -4.09B -1.61B -20B -1.59B -1.56B -68.86B -504M -441M -407M -375M -707M -48.56B -722M -4.86B -1.91B -23.78B -1.89B -1.85B -81.88B
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
17/07/26 US$12.35 -0.64% 7,160,838
16/07/26 US$12.43 -6.61% 11,929,833
15/07/26 US$13.31 -0.60% 3,358,653
14/07/26 US$13.39 +1.55% 2,798,237
13/07/26 US$13.19 -3.34% 3,033,289
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.35USD
Average target price
24.47USD
Spread / Average Target
+98.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPS Stock